BrightGene Bio-Medical Hits Day Low at CNY 33.78 Amid Price Pressure

BrightGene Bio-Medical Technology Co., Ltd. experienced a notable decline today, with the stock dropping by 3.6% and reaching an intraday low of CNY 33.78. This performance contrasts with the China Shanghai Composite, which fell by 1.16% on the same day. Over the past week, BrightGene's stock has decreased by 1.51%, while the broader index saw a slight decline of 1.32%. In terms of longer-term performance, BrightGene has faced significant challenges, with a staggering 66.48% drop over the past year, compared to a 5.99% increase in the Shanghai Composite. Year-to-date, the stock is down 29.56%, while the index has only declined by 3.92%. Financial metrics indicate a high debt-to-equity ratio of 0.67, and the company has reported negative results for six consecutive quarters. The return on equity stands at a low 1.44%, and the price-to-book ratio is notably high at 7.35. Despite a dividend yield of 0.25%, the company's profitability remains a concern, with net profit and operating cash flow showing significant declines.